Ricky Goldwasser
Stock Analyst at Morgan Stanley
(4.24)
# 457
Out of 5,041 analysts
228
Total ratings
65.19%
Success rate
9.87%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNC Centene | Maintains: Equal-Weight | $28 → $38 | $34.07 | +11.54% | 14 | Oct 14, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $325 → $395 | $362.50 | +8.97% | 20 | Sep 12, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $279.49 | +9.49% | 17 | Jul 25, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $71 → $60 | $66.84 | -10.23% | 10 | Apr 24, 2025 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $220 → $184 | $197.04 | -6.62% | 22 | Feb 5, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $5.20 | +92.31% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $3.95 | +39.24% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $19.29 | -61.12% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $17.51 | -31.47% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $182.18 | -20.41% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $163.32 | +123.49% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $801.67 | -47.61% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $5.57 | +2,054.40% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $290.65 | +113.31% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $342.35 | +46.05% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $81.93 | +51.35% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $301.78 | +5.37% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $161.89 | -56.76% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $220.52 | -11.57% | 6 | Oct 21, 2020 |
Centene
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $28 → $38
Current: $34.07
Upside: +11.54%
UnitedHealth Group
Sep 12, 2025
Maintains: Overweight
Price Target: $325 → $395
Current: $362.50
Upside: +8.97%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $279.49
Upside: +9.49%
Doximity
Apr 24, 2025
Maintains: Equal-Weight
Price Target: $71 → $60
Current: $66.84
Upside: -10.23%
Charles River Laboratories International
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $220 → $184
Current: $197.04
Upside: -6.62%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $5.20
Upside: +92.31%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $3.95
Upside: +39.24%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $19.29
Upside: -61.12%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $17.51
Upside: -31.47%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $182.18
Upside: -20.41%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $163.32
Upside: +123.49%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $801.67
Upside: -47.61%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $5.57
Upside: +2,054.40%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $290.65
Upside: +113.31%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $342.35
Upside: +46.05%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $81.93
Upside: +51.35%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $301.78
Upside: +5.37%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $161.89
Upside: -56.76%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $220.52
Upside: -11.57%